The pharmaceutical equipment market will continue to grow in the future. How can companies seize the opportunity?

Pharmaceutical equipment is the upstream of the pharmaceutical industry, and its technical level determines the strength of the pharmaceutical level
.
In recent years, driven by the high boom of the downstream pharmaceutical industry and the support of favorable policies, China's pharmaceutical equipment has accelerated the upgrade, and the industry market scale is on the rise.
In 2020, it has reached 35 billion yuan.
The industry is expected to continue to grow in the future.
By 2021 The year is approaching 40 billion yuan, and will increase to about 44 billion yuan by 2022.
From the data, it can be seen that China's pharmaceutical equipment market has a promising future
.
So, as the new year is approaching, how should pharmaceutical equipment companies seize the opportunity? Pharmaceutical equipment (picture source: Pharmaceutical Network) "The development situation of the pharmaceutical equipment industry is undoubtedly good, but opportunities and challenges often coexist.
Enterprises should start from the bottleneck and solve them one by one
.
" Some insiders pointed out that at present, talents, R&D level, Service quality and other aspects are the shortcomings of domestic pharmaceutical equipment companies.
Only by strengthening the research, domestic pharmaceutical machinery companies can reach a new level
.
Among them, the lack of high-level talents is a hurdle that hinders the high-quality development of the pharmaceutical equipment industry
.
At present, China’s manufacturing industry, including the pharmaceutical equipment industry, is transitioning to a high-quality development stage.
As a knowledge- and technology-intensive industry, the pharmaceutical equipment industry’s demand for talents has been increasing in recent years, but according to many pharmaceutical machinery companies , "Failure to recruit" and "Failure to retain people" phenomena often occur in the industry
.
Regarding the shortcomings of talents in pharmaceutical machinery companies, the industry suggests that, on the one hand, companies need to pay more attention to talents and attract and retain talents in terms of remuneration, promotion space, and benefits
.
In recent years, it can be seen that pharmaceutical machinery companies including Chutian and Tofflon have paid more attention to talent training, recruiting talents through various methods such as cooperation with schools and enterprises, and improving salaries; on the other hand, industry construction is also needed.
A sound human resources policy system, and relevant policy and system documents supporting the development of pharmaceutical machinery talents have been issued, so that talents can concentrate on doing "big things" and help the development of pharmaceutical machinery enterprises and the industry
.
Compared with European and American countries, insufficient R&D level is also a shortcoming of domestic pharmaceutical equipment companies.

.
In recent years, with the gradual penetration of the Internet, digitalization, cloud computing and other technologies, the pharmaceutical equipment industry has also deepened the application of these new technologies, and has accelerated its development in the direction of flexibility, modularization, intelligence, and integration.
In this process, a solid R&D strength is required to support the integration and application of new technologies, which is a big test for the R&D level of the enterprise
.
Take the domestic pharmaceutical giants Chutian Technology and Dongfulong as examples.
In recent years, the two giants have made great efforts in R&D investment, and the proportion of R&D expenses in revenue has gradually increased.
Among them, Chutian Technology’s annual R&D investment is about It accounts for about 8% to 10% of sales revenue, but compared with European and American companies, the proportion of R&D investment and R&D expenses urgently need to be further increased
.
In addition, in terms of service quality, as the pace of domestic substitution has accelerated in recent years, more and more pharmaceutical machinery companies have opened the road to international layout, but there is still room for improvement in service levels, which is mainly reflected in overseas sales channels.
imperfect, international team understaffed and so on
.
The industry suggests that large pharmaceutical companies can use their first-mover advantages in overseas markets to strengthen the training of international teams, carry out localization, and seize more overseas market opportunities
.
And small and medium-sized enterprises can concentrate on cultivating market segments, build their own brand advantages, broaden sales channels, and promote products and services to the international market
.